应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
FULC Fulcrum Therapeutics
盘后交易 08-12 19:19:14 EDT
3.72
+0.03
+0.81%
盘后
3.73
+0.01
+0.26%
16:47 EDT
最高
3.74
最低
3.62
成交量
90.14万
今开
3.70
昨收
3.69
日振幅
3.39%
总市值
2.84亿
流通市值
1.87亿
总股本
7,630万
成交额
334.17万
换手率
1.80%
流通股本
5,021万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Fulcrum Therapeutics 提交SEC文件：计划裁员85%，员工数将从57人减至9人，预计2026年第二季度完成
美股速递 · 06-05
Fulcrum Therapeutics 提交SEC文件：计划裁员85%，员工数将从57人减至9人，预计2026年第二季度完成
Fulcrum Therapeutics：终止镰状细胞病药物Pociredir后批准重组计划 - 美国证券交易委员会文件披露
美股速递 · 06-05
Fulcrum Therapeutics：终止镰状细胞病药物Pociredir后批准重组计划 - 美国证券交易委员会文件披露
Fulcrum Therapeutics 宣布放弃镰状细胞病药物研发 股价盘前暴跌49.4%至3.25美元
美股速递 · 06-02
Fulcrum Therapeutics 宣布放弃镰状细胞病药物研发 股价盘前暴跌49.4%至3.25美元
Fulcrum Therapeutics宣布终止镰状细胞病Pociredir项目并启动战略评估
美股速递 · 06-02
Fulcrum Therapeutics宣布终止镰状细胞病Pociredir项目并启动战略评估
谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗
投资观察 · 05-08
谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗
Fulcrum Therapeutics终止与Camp4 Therapeutics的授权协议
美股速递 · 04-27
Fulcrum Therapeutics终止与Camp4 Therapeutics的授权协议
Fulcrum Therapeutics一季度末持有3.333亿美元现金及证券 资金储备可支撑至2029年
美股速递 · 04-27
Fulcrum Therapeutics一季度末持有3.333亿美元现金及证券 资金储备可支撑至2029年
Fulcrum Therapeutics公布2026年第一季度业务进展与财务业绩
美股速递 · 04-27
Fulcrum Therapeutics公布2026年第一季度业务进展与财务业绩
Fulcrum Therapeutics任命Josh Lehrer加入董事会
投资观察 · 04-27
Fulcrum Therapeutics任命Josh Lehrer加入董事会
Fulcrum Therapeutics, Inc.盘中异动 大幅拉升5.01%报9.01美元
市场透视 · 02-25
Fulcrum Therapeutics, Inc.盘中异动 大幅拉升5.01%报9.01美元
Fulcrum Therapeutics：2025年末现金及等价物与有价证券达3.523亿美元，资金可支撑运营至2029年
美股速递 · 02-24
Fulcrum Therapeutics：2025年末现金及等价物与有价证券达3.523亿美元，资金可支撑运营至2029年
Fulcrum Therapeutics公布Pociredir治疗镰状细胞病1B期Pioneer试验20毫克剂量组12周积极结果
美股速递 · 02-24
Fulcrum Therapeutics公布Pociredir治疗镰状细胞病1B期Pioneer试验20毫克剂量组12周积极结果
Fulcrum Therapeutics公布2025年第四季度及全年业务亮点与财务业绩
美股速递 · 02-24
Fulcrum Therapeutics公布2025年第四季度及全年业务亮点与财务业绩
Fulcrum Therapeutics, Inc.盘中异动 下午盘急速下跌5.41%报2.97美元
市场透视 · 2025-03-11
Fulcrum Therapeutics, Inc.盘中异动 下午盘急速下跌5.41%报2.97美元
Fulcrum Therapeutics, Inc.盘中异动 股价大跌5.56%报3.06美元
市场透视 · 2025-03-04
Fulcrum Therapeutics, Inc.盘中异动 股价大跌5.56%报3.06美元
Fulcrum Therapeutics, Inc.2024财年实现净利润-9.73百万美元，同比增加90.00%
市场透视 · 2025-03-01
Fulcrum Therapeutics, Inc.2024财年实现净利润-9.73百万美元，同比增加90.00%
Fulcrum Therapeutics, Inc.盘中异动 早盘股价大跌5.95%
市场透视 · 2025-02-25
Fulcrum Therapeutics, Inc.盘中异动 早盘股价大跌5.95%
福尔克姆治疗公司第四季度GAAP每股亏损$(0.31)，好于预期的$(0.32)
财报速递 · 2025-02-25
福尔克姆治疗公司第四季度GAAP每股亏损$(0.31)，好于预期的$(0.32)
Fulcrum Therapeutics(FULC.US)：2024年Q4财报实现营收0美元，前值为87.1万美元；每股收益为-0.31美元，前值为-0.40美元，预期值为-0.29美元。
金融界 · 2025-02-25
Fulcrum Therapeutics(FULC.US)：2024年Q4财报实现营收0美元，前值为87.1万美元；每股收益为-0.31美元，前值为-0.40美元，预期值为-0.29美元。
Fulcrum Therapeutics, Inc.盘中异动 早盘快速下跌5.49%报4.13美元
市场透视 · 2025-01-13
Fulcrum Therapeutics, Inc.盘中异动 早盘快速下跌5.49%报4.13美元
公司概况
公司名称：
Fulcrum Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
Fulcrum Therapeutics, Inc.于2015年8月18日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于在高度未满足的医疗需求领域改善基因定义疾病患者的生活，最初的重点是罕见病。该公司开发了一种专有产品引擎，该公司使用该引擎来系统地识别和验证细胞药物靶点，这些靶点可以潜在地调节基因表达，以治疗已知的基因定义疾病的根本原因。该公司正在使用产品引擎来识别可以被小分子下药的靶点，而不管基因错误表达的特定潜在机制如何。该公司已确定药物靶点，以治疗面肩肱肌营养不良症（FSHD）和某些血红蛋白病（即镰状细胞病（SCD））和b-地中海贫血的根本原因。
发行价格：
--
{"stockData":{"symbol":"FULC","market":"US","secType":"STK","nameCN":"Fulcrum Therapeutics","latestPrice":3.72,"timestamp":1786564800000,"preClose":3.69,"halted":0,"volume":901372,"hourTrading":{"tag":"盘后","latestPrice":3.7297,"preClose":3.72,"latestTime":"16:47 EDT","volume":3099,"amount":11531.155872,"timestamp":1786567678029,"change":0.0097,"changeRate":0.002608,"amplitude":0.002688},"delay":0,"changeRate":0.008130081300813075,"floatShares":50211400,"shares":76297257,"eps":-1.210432,"marketStatus":"盘后交易","change":0.03,"latestTime":"08-12 19:19:14 EDT","open":3.7,"high":3.74,"low":3.615,"amount":3341686.7016992,"amplitude":0.033875,"askPrice":3.78,"askSize":2000,"bidPrice":3.55,"bidSize":7500,"shortable":3,"etf":0,"ttmEps":-1.210432,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1786579200000},"marketStatusCode":4,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":3.69,"preHourTrading":{"tag":"盘前","latestPrice":3.7,"preClose":3.69,"latestTime":"09:22 EDT","volume":442,"amount":1644.824324,"timestamp":1786540970669,"change":0.01,"changeRate":0.00271,"amplitude":0.108401},"postHourTrading":{"tag":"盘后","latestPrice":3.7297,"preClose":3.72,"latestTime":"16:47 EDT","volume":3099,"amount":11531.155872,"timestamp":1786567678029,"change":0.0097,"changeRate":0.002608,"amplitude":0.002688},"volumeRatio":0.793123,"impliedVol":0.2124,"impliedVolPercentile":0.0279},"requestUrl":"/m/hq/s/FULC/wiki","defaultTab":"wiki","newsList":[{"id":"1120433947","title":"Fulcrum Therapeutics 提交SEC文件：计划裁员85%，员工数将从57人减至9人，预计2026年第二季度完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1120433947","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120433947?lang=zh_cn&edition=full","pubTime":"2026-06-05 04:11","pubTimestamp":1780603876,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics 已向美国证券交易委员会提交文件，宣布将大幅缩减员工规模。根据计划，公司将裁员约85%，员工总数将从目前的57人减少至仅9人。此项重组预计在2026年第二季度完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127254541","title":"Fulcrum Therapeutics：终止镰状细胞病药物Pociredir后批准重组计划 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1127254541","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127254541?lang=zh_cn&edition=full","pubTime":"2026-06-05 04:11","pubTimestamp":1780603874,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics在一份提交给美国证券交易委员会的文件中披露，公司已批准一项重组计划。此决定是在其终止针对镰状细胞病的在研药物Pociredir的开发之后作出的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123726516","title":"Fulcrum Therapeutics 宣布放弃镰状细胞病药物研发 股价盘前暴跌49.4%至3.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123726516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123726516?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:05","pubTimestamp":1780391116,"startTime":"0","endTime":"0","summary":"在Fulcrum Therapeutics宣布终止其镰状细胞病治疗药物的开发计划后，公司股价在盘前交易时段遭遇重挫，暴跌49.4%，报收于3.25美元。这一决定直接触发了市场对公司未来前景的深度担忧，导致投资者信心严重受挫，股价大幅跳水。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105534675","title":"Fulcrum Therapeutics宣布终止镰状细胞病Pociredir项目并启动战略评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1105534675","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105534675?lang=zh_cn&edition=full","pubTime":"2026-06-02 04:06","pubTimestamp":1780344395,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics宣布，将终止其针对镰状细胞病的Pociredir研发项目，并同时启动一项全面的战略评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139383641","title":"谷歌母公司Alphabet披露持仓变动：增持PayPay与CME集团，清仓德康医疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139383641","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139383641?lang=zh_cn&edition=full","pubTime":"2026-05-08 18:36","pubTimestamp":1778236606,"startTime":"0","endTime":"0","summary":"根据最新提交的监管文件显示，Alphabet公司在截至2026年3月31日的季度内对其投资组合进行了显著调整。这家科技巨头披露持有PayPay公司310万份赞助存托凭证，同时增持Planet Labs Pbc公司10.4%的A类股份，使其总持股量达到3520万股。在金融领域，Alphabet报告持有芝加哥商品交易所约350万股股份。此外，Alphabet还披露持有Ethos Technologies公司380万份A类股份，同时将其在Revolution Medicines公司的持股比例削减1.6%，目前持有330万股。这些持仓变动均以2025年12月31日为基准进行对比。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0784385170.HKD","LU2095319765.USD","LU0772969993.USD","IE00BK4W5M84.HKD","LU2505996509.AUD","SG9999018857.SGD","LU0174119429.USD","LU0310799852.SGD","LU1674673691.USD","LU0648001328.SGD","LU0130102774.USD","LU2750360641.GBP","LU1852331112.SGD","LU0950375773.USD","SG9999014880.SGD","LU2326559502.SGD","LU1935042991.SGD","IE00B3T34201.USD","LU0256863811.USD","LU0211328371.USD","LU0080751232.USD","LU2168564065.EUR","BK4503","IE000SO60NU8.SGD","BK4612","IE000F7OJYX1.SGD","LU0289961442.SGD","BK4514","LU0215105999.USD","BK4581","LU1823568750.SGD","IE0004091025.USD","LU1803068623.USD","LU0314104364.USD","LU0154236417.USD","LU0528227936.USD","LU1935042215.USD","LU1121112475.USD","LU2168564495.EUR","IE00BMPRXR70.SGD","BK4538","LU1400636491.USD","HK0000304805.HKD","LU1923623000.USD","LU0731783048.USD","LU0820562030.AUD","LU0107464264.USD","LU0234572021.USD","LU1429558221.USD","LU1599440770.SGD","LU2065169927.USD","LU0738911758.USD","IE00B19Z8W00.USD","IE00BWXC8680.SGD","LU2264538146.SGD","LU1868837300.USD","LU2746668461.USD","SG9999014898.SGD","LU0787776722.HKD","IE00BKVL7J92.USD","LU2471134523.USD","LU0203345920.USD","IE00B19Z3581.USD","IE00BQXX3F31.USD","LU0310800379.SGD","LU1119994496.HKD","LU0077335932.USD","LU2360106780.USD","LU2491050071.SGD","LU0234570918.USD","LU0823434740.USD","LU1244550494.USD","LU1280957306.USD","PLU","LU2491049909.HKD","LU1366333091.USD","BK4548","LU0820561909.HKD","LU1481011911.USD","LU1629891620.HKD","LU0545039389.USD","LU0211326755.USD","LU0494093205.USD","LU1868837136.USD","LU0466842654.USD","LU0048584097.USD","LU0289739343.SGD","IE00BVYPNV92.GBP","LU1400636657.SGD","LU1201861249.SGD","LU2357305700.SGD","LU2756315318.SGD","LU2404859741.USD","LU2381873111.SGD","SGXZ99366536.SGD","GOOW","LU0128525689.USD","SGXZ81514606.USD","LU2954938101.SGD","LU2430703095.HKD","BK4574","LU0198837287.USD","LU0251132253.USD","LU0985320562.USD","WGS","IE00BGHQF631.EUR","LU0106261612.USD","LU2106854487.HKD","LU2433249047.HKD","LU0276348264.USD","LU0225283273.USD","LU2430703178.SGD","LU1066051225.USD","LU1720051108.HKD","GB00B4QBRK32.GBP","LU1868836591.USD","BK4007","IE00BQXX3D17.EUR","IE00BDCRKT87.USD","IE00BJTD4N35.SGD","LU2471134879.HKD","HK0000819398.USD","LU1244550221.USD","IE000MB6IJN5.SGD","LU0096362180.USD","LU2213496289.HKD","LU2125154778.USD","LU0251131958.USD","IE00BVYPNW00.USD","LU0689626769.HKD","LU1642822529.SGD","SG9999017495.SGD","LU1732800096.USD","LU0130518102.USD","LU1815333072.USD","LU1868836757.USD","LU2362540622.SGD","LU2092937148.SGD","LU2125909247.SGD","LU1043141396.HKD","LU1066053197.SGD","LU0057025933.USD","LU1201861165.SGD","LU0477156953.USD","IE00BMPRXQ63.HKD","LU1267930813.SGD","LU0208291251.USD","IE00B7SZLL34.SGD","BK4602","LU1988902786.USD","LU0267386448.USD","LU2462157665.USD","LU0545562505.USD","LU2471134796.USD","LU2242650005.HKD","LU1548497426.USD","GGLL","LU0266013472.USD","LU2247934214.USD","LU1116320737.USD","LU0061475181.USD","IE00B19Z3B42.SGD","LU1496350502.SGD","LU0289960550.SGD","RGEN","LU2092627202.USD","LU0130517989.USD","BK4504","LU0345774631.USD","LU0642271901.SGD","LU1228905037.USD","PL","IE00B42XCP33.USD","LU0345769631.USD","BK4527","LU1935043023.USD","LU2271345857.HKD","LU1951200564.SGD","LU0943347566.SGD","LU1894683264.USD","LU2065171311.SGD","LU0792757196.USD","LU0980610538.SGD","LU1202635105.USD","LU2250418816.HKD","LU2999663052.SGD","SG9999018865.SGD","LU1880398554.USD","IE00BSNM7G36.USD","GB00B4LPDJ14.GBP","HK0000304797.USD","LU0823421416.USD","LU0069063385.USD","LU2244417387.USD","LU2506951875.HKD","LU0314106906.USD","LU0994945656.USD","BK4551","LU2210149790.SGD","LU2168563687.JPY","LU1585245621.USD","LU0496365809.HKD","LU0784384876.USD","LU1670627923.USD","LU1989764748.USD","LU0265550946.USD","LU1366192091.USD","BK4123","LU2133065610.SGD","LU0128525929.USD","LU0949170426.SGD","LU2191332357.HKD","LU1670756490.USD","LU0477156797.USD","IE000BZT7R73.USD","LU1032955483.USD","LU0823417737.USD","LU2756315664.SGD","LU0316494557.USD","LU0265550359.USD","LU1633808545.USD","LU1066051811.HKD","LU0109391861.USD","GOU","LU2860962120.EUR","LU1496350171.SGD","LU0661504455.SGD","IE0034235295.USD","LU1267930490.SGD","LU1718418525.SGD","IE00BKPKM429.USD","LU0889566641.SGD","LU2275660780.HKD","LU0187121727.USD","IE0034235303.USD","LU0094547139.USD","LU0106261372.USD","BK4121","LU1084165304.USD","LU0320765489.SGD","LU0417517546.SGD","LU2023250504.SGD","LU2471134952.CNY","LU0061474960.USD","LU2430703251.USD","LU1400636574.HKD","LU0056508442.USD","LU2746668974.SGD","IE00BLSP4239.USD","LU2089283258.USD","LU0557290698.USD","BK4585","LU0784383803.USD","LU1674673428.USD","LU0795875086.SGD","LU0127658192.USD","LU1267930730.SGD","GGLS","LU2462591277.SGD","LU0130103400.USD","LU0708994859.HKD","LU2506952097.USD","SG9999015952.SGD","LU2602419157.SGD","LU0029864427.USD","LU2362541273.HKD","LU0444971666.USD","LU0353189763.USD","LU1323610961.USD","LU2750360997.AUD","IE00BHPRN162.USD","BK4579","LU0648000940.SGD","LU0957791311.USD","LU2403377893.USD","LU2491050154.USD","LU0757428866.USD","IE0034235188.USD","LU0048573561.USD","LU2462591350.SGD","IE0001KFT4U8.USD","BK4532","LU1815336760.USD","LU1880398471.USD","LU2417539215.USD","BK4543","IE00BKDWB100.SGD","LU0203347892.USD","GOOGL","LU0672654240.SGD","LU1261432733.SGD","LU1481011671.HKD","LIFE","LU0211331839.USD","LU0823417653.USD","LU2065170008.USD","LU0553294199.USD","IE00B19Z9505.USD","LU1043141123.HKD","LU2347655156.SGD","BK4173","LU0476273544.USD","LU1059921491.USD","LU0097036916.USD","LU1551013342.USD","LU0345770993.USD","LU0158827948.USD","LU0342679015.USD","LU2077746001.SGD","LU0312595415.SGD","LU1145028129.USD","LU1509826696.USD","BK4563","LU1917777945.USD","LU0170899867.USD","LU0310800965.SGD","BK4534","IE00BLSP4452.SGD","LU1989764664.SGD","BK4082","GOOP","LU2237438978.USD","LU0211326839.USD","SG9999015978.USD","LU2242649171.HKD","LU2111349929.HKD","LU0061474705.USD","LU0426417589.USD","LU0149725797.USD","LU2028103732.USD","LU0138981039.USD","BK4561","LU2023251221.USD","LU1791710582.SGD","LU0302445910.USD","LU0210533765.USD","LU2456880835.USD","RVMD","LU1267930227.SGD","LU0820561818.USD","LU0690374961.EUR","LU1815336091.USD","LU2210150020.SGD","LU0345774391.USD","LU0345769128.USD","IE00BQXX3C00.GBP","LU0175139822.USD","IE00BZ1G4Q59.USD","LU2098885051.SGD","IE00B3PB1722.GBP","LU2065171402.SGD","LU0256863902.USD","LU1914381329.SGD","LU2087625088.SGD","LU2265009873.SGD","GOOY","IE00BJTD4V19.USD","IE00BYXW3230.USD","LU1778281490.HKD","LU1221951046.USD","LU0211327993.USD","IE00BJLML261.HKD","LU2360032135.SGD","LU0353189680.USD","CME","LU2097344431.USD","IE00BFMHRM44.USD","LU0640476718.USD","BK4077","LU1699723380.USD","GOOX","IE00BDRTCR15.USD","LU1221951129.SGD","LU0868494617.USD","LU0912757837.SGD","BK4196","HK0000532082.HKD","FULC","BK4588","BK4533","LU1645745479.HKD","LU0323591593.USD","LU0345768153.USD","LU0006306889.USD","BK4592","LU0976567544.SGD","LU0070217475.USD","LU1670628061.USD","LU0742534661.SGD","LU0795875169.SGD","BK4139","LU0052756011.USD","SG9999014914.USD","LU0354030511.USD","LU1974910355.USD","LU1066051498.USD","SG9999015986.USD","SG9999015945.SGD","BK4576","LU1935043536.SGD","LU0472753341.HKD","LU1116320901.HKD","LU0426412945.USD","LU2505996681.GBP","LU1989772923.USD","LU1791710400.SGD","LU0708995401.HKD","LU1303367103.USD","LU0731783394.SGD","IE00BK4W5L77.USD","LU1046421795.USD","LU2592432038.USD","LU2362541513.USD","LU1232071149.USD","LU1301847155.USD","LU0683600562.USD","LU1732799900.SGD","IE000WAW04H5.SGD","BK4573","LU2125154935.USD","LU0957808578.USD","LU2023250843.SGD","IE0004086264.USD","SGXZ31699556.SGD","LU0949170772.SGD","LU1551013425.SGD","IE00B19Z8X17.USD","IE0000B7K699.USD","LU1153585028.USD","LU2097829019.USD","LU2125909593.SGD","LU0251142724.SGD","LU0942090050.USD","LU1228905540.USD","BK4227","IE00BBT3K403.USD","LU0157215616.USD","LU2097344357.USD","LU1804176565.USD","LU0823434583.USD","SG9999014906.USD","LU2054465674.USD","LU0124676726.USD","LU1244550577.SGD","PAYP","LU1267930573.SGD","LU1196500208.SGD","LU0354030438.USD","LU0012050646.USD","LU2404859667.USD","LU1923622614.USD","IE00B1XK9C88.USD","LU1935042488.USD","LU2023250330.USD","LU1064131342.USD","LU0964807845.USD","LU0096364046.USD","LU1316542783.SGD","LU1720051017.SGD","LU0690374615.EUR","BK4550","LU2089284900.SGD","IE00BMPRXN33.USD","LU0784385840.USD","LU1430594728.SGD","LU1839511570.USD","SGXZ51526630.SGD","LU1571399168.USD","LU0689472784.USD","LU0823421333.USD","LU1868836914.USD","LU2087621335.USD","LU0511384066.AUD","LU0320765059.SGD","BK4566","DXCM","LU1435385759.SGD","LU0345768740.USD","IE0002270589.USD","LU0868494708.USD","LU1894683348.USD","LU0143551892.USD","LU0348723411.USD","LU2420271590.USD","LU1989772840.SGD","LU0742537680.HKD","LU0345770308.USD","BK4112","LU1506573853.SGD","LU1951198990.SGD","LU2506952170.USD","SG9999000418.SGD","LU2506951958.HKD","LU0158827781.USD","LU2063271972.USD","LU1235294995.USD","BK4598","IE00BN8TJ469.HKD","LU0070302665.USD","LU2236285917.USD","LU2211815571.USD","IE00B1BXHZ80.USD","LU0444973449.USD","IE000M9KFDE8.USD","LU1003077747.HKD","LU0882574139.USD","LU0011850046.USD","IE00BDGV0183.EUR","LU2168564222.USD","LU2168564149.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152426060","title":"Fulcrum Therapeutics终止与Camp4 Therapeutics的授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1152426060","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152426060?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:23","pubTimestamp":1777288982,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会文件显示，Fulcrum Therapeutics Inc已于4月23日正式终止了与Camp4 Therapeutics Corp.于2023年7月5日签署的授权协议。该协议的终止标志着两家生物技术公司为期九个月的合作关系画上句点。对于专注开发基因调控疗法的Fulcrum而言，此次协议终止可能意味着公司将重新评估其管线战略布局。而Camp4作为专注于利用调控RNA技术开发变革性疗法的生物科技企业，其对外合作策略亦可能随之调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","CAMP","BK4007","BK4020","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184655270","title":"Fulcrum Therapeutics一季度末持有3.333亿美元现金及证券 资金储备可支撑至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1184655270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184655270?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:16","pubTimestamp":1777288598,"startTime":"0","endTime":"0","summary":"生物制药公司Fulcrum Therapeutics（股票代码：FULC）最新财务数据显示，截至2026年第一季度末，公司持有的现金及有价证券总额达3.333亿美元。基于当前运营规划测算，该资金规模预计可支持公司临床研发及日常运营持续至2029年。\n这一充足的资金储备为该公司推进其核心候选药物FTX-6059（用于镰状细胞病治疗）的临床开发提供了坚实保障。同时，资金缓冲能力也使公司能够灵活应对生物技术行业常见的研发周期长、监管审批不确定性等挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100712460","title":"Fulcrum Therapeutics公布2026年第一季度业务进展与财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1100712460","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100712460?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:02","pubTimestamp":1777287747,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics近日披露了2026年第一季度的重大业务动态及财务数据。报告期内，该公司在核心研发项目取得关键里程碑，同时保持了稳健的财务表现。此次公布的业绩指标为投资者评估该生物技术企业的战略执行情况提供了最新依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182566662","title":"Fulcrum Therapeutics任命Josh Lehrer加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1182566662","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182566662?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:58","pubTimestamp":1777287509,"startTime":"0","endTime":"0","summary":"马萨诸塞州剑桥，2026年4月27日——临床阶段生物制药公司Fulcrum Therapeutics今日宣布，任命医学博士、哲学硕士、美国心脏病学院院士Josh Lehrer为其董事会独立董事。他现任临床阶段生物技术公司Marea Therapeutics的首席执行官兼董事会成员。Fulcrum Therapeutics是一家临床阶段生物制药公司，致力于研发改善罕见血液疾病患者生活的小分子药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4007","FULC","BK4022","R","SCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614706730","title":"Fulcrum Therapeutics, Inc.盘中异动 大幅拉升5.01%报9.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614706730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614706730?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:19","pubTimestamp":1772032787,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日23时19分，Fulcrum Therapeutics, Inc.股票出现异动，股价大幅拉升5.01%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Larimar Therapeutics, Inc.、Moolec Science Sa C/Wts 30/01/2028、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Quince Therapeutics, Inc.、Cardio Diagnostics Holdings Inc.、Genprex, Inc.较为活跃，换手率分别为180.99%、119.26%、33.60%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Larimar Therapeutics, Inc.、曼恩凯德生物医疗，振幅分别为65.42%、45.40%、37.36%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225231948a4c7c638&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225231948a4c7c638&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FULC","BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119356302","title":"Fulcrum Therapeutics：2025年末现金及等价物与有价证券达3.523亿美元，资金可支撑运营至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1119356302","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119356302?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:12","pubTimestamp":1771935167,"startTime":"0","endTime":"0","summary":"生物制药公司Fulcrum Therapeutics近日披露，截至2025年末，其持有的现金、现金等价物及有价证券总额达到3.523亿美元。这一资金规模预计可为公司运营提供支持直至2029年，展现出强劲的财务韧性和长期发展潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141228970","title":"Fulcrum Therapeutics公布Pociredir治疗镰状细胞病1B期Pioneer试验20毫克剂量组12周积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1141228970","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141228970?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:05","pubTimestamp":1771934701,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics宣布，其在研药物Pociredir针对镰状细胞病的1B期Pioneer临床试验取得积极进展。该试验中20毫克剂量组完成了12周的治疗评估，结果显示令人鼓舞。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185936555","title":"Fulcrum Therapeutics公布2025年第四季度及全年业务亮点与财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1185936555","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185936555?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:03","pubTimestamp":1771934639,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics（简称FULC）近日正式披露了2025年第四季度及全年的核心业务进展与财务数据报告。公司在此期间实现了多项关键里程碑，包括研发管线的突破性进展与战略合作的深化。财务方面，Fulcrum Therapeutics同步公布了详细的营收、支出及现金流状况，展现出企业在创新药研发领域的持续投入与稳健运营。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518797203","title":"Fulcrum Therapeutics, Inc.盘中异动 下午盘急速下跌5.41%报2.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518797203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518797203?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:02","pubTimestamp":1741626172,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时02分，Fulcrum Therapeutics, Inc.股票出现异动，股价大幅下挫5.41%。截至发稿，该股报2.97美元/股，成交量14.2611万股，换手率0.26%，振幅4.33%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.73%。其相关个股中，Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为4138.96%、3793.09%、981.72%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 29/04/2026 、Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为88.14%、78.32%、54.65%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010252964060a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010252964060a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FULC","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677389","title":"Fulcrum Therapeutics, Inc.盘中异动 股价大跌5.56%报3.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677389?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:40","pubTimestamp":1741099209,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时40分，Fulcrum Therapeutics, Inc.股票出现波动，股价大幅下跌5.56%。截至发稿，该股报3.06美元/股，成交量8270股，换手率0.02%，振幅1.08%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.13%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1106.78%、1100.10%、436.25%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Windtree Therapeutics, Inc.，振幅分别为37.67%、22.25%、19.21%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224009a25f0785&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224009a25f0785&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","FULC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516376038","title":"Fulcrum Therapeutics, Inc.2024财年实现净利润-9.73百万美元，同比增加90.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516376038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516376038?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:01","pubTimestamp":1740758461,"startTime":"0","endTime":"0","summary":"3月1日，Fulcrum Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-9.73百万美元，同比增加90.00%；其中营业收入为80.00百万美元，同比增加2746.98%，每股基本收益为-0.16美元。机构评级：截至2025年3月1日，当前有6家机构对Fulcrum Therapeutics, Inc.目标价做出预测，其中目标均价为5.67美元，其中最低目标价为2.00美元，最高目标价为14.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000155a258185d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301000155a258185d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","FULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514906570","title":"Fulcrum Therapeutics, Inc.盘中异动 早盘股价大跌5.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514906570","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514906570?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:33","pubTimestamp":1740494027,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时33分，Fulcrum Therapeutics, Inc.股票出现异动，股价快速下跌5.95%。截至发稿，该股报3.48美元/股，成交量9438股，换手率0.02%，振幅4.59%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为760.67%、470.72%、244.50%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp、Dominari Holdings Inc.，振幅分别为20.51%、14.67%、11.73%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223347a253879e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223347a253879e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","FULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132526931","title":"福尔克姆治疗公司第四季度GAAP每股亏损$(0.31)，好于预期的$(0.32)","url":"https://stock-news.laohu8.com/highlight/detail?id=1132526931","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132526931?lang=zh_cn&edition=full","pubTime":"2025-02-25 20:30","pubTimestamp":1740486651,"startTime":"0","endTime":"0","summary":"福尔克姆治疗公司报告季度每股亏损$，好于分析师预期的$，超出预期3.13%。相比去年同期每股亏损$，这是22.5%的增长。以上内容来自Benzinga Earnings专栏，原文如下：$Fulcrum Therapeutics$ reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 3.13 percent. This is a 22.5 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福尔克姆治疗公司第四季度GAAP每股亏损$(0.31)，好于预期的$(0.32)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514609364","title":"Fulcrum Therapeutics(FULC.US)：2024年Q4财报实现营收0美元，前值为87.1万美元；每股收益为-0.31美元，前值为-0.40美元，预期值为-0.29美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609364","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514609364?lang=zh_cn&edition=full","pubTime":"2025-02-25 20:11","pubTimestamp":1740485514,"startTime":"0","endTime":"0","summary":"Fulcrum Therapeutics(FULC.US)：2024年Q4财报实现营收0美元，前值为87.1万美元；每股收益为-0.31美元，前值为-0.40美元，预期值为-0.29美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25201148381039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["FULC","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503396586","title":"Fulcrum Therapeutics, Inc.盘中异动 早盘快速下跌5.49%报4.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503396586","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503396586?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:36","pubTimestamp":1736778990,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时36分，Fulcrum Therapeutics, Inc.股票出现异动，股价急速下挫5.49%。截至发稿，该股报4.13美元/股，成交量1.1376万股，换手率0.02%，振幅4.12%。Fulcrum Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.99%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3508.04%、2126.83%、393.32%，振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、Champions Oncology, Inc.、Phio Pharmaceuticals Corp.，振幅分别为104.79%、102.87%、61.54%。Fulcrum Therapeutics, Inc.公司简介：Fulcrum Therapeutics Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223630a22040ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113223630a22040ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FULC","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fulcrumtx.com","stockEarnings":[{"period":"1week","weight":-0.0289},{"period":"1month","weight":0.0543},{"period":"3month","weight":-0.491},{"period":"6month","weight":-0.6602},{"period":"1year","weight":-0.418},{"period":"ytd","weight":-0.6737}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fulcrum Therapeutics, Inc.于2015年8月18日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，专注于在高度未满足的医疗需求领域改善基因定义疾病患者的生活，最初的重点是罕见病。该公司开发了一种专有产品引擎，该公司使用该引擎来系统地识别和验证细胞药物靶点，这些靶点可以潜在地调节基因表达，以治疗已知的基因定义疾病的根本原因。该公司正在使用产品引擎来识别可以被小分子下药的靶点，而不管基因错误表达的特定潜在机制如何。该公司已确定药物靶点，以治疗面肩肱肌营养不良症（FSHD）和某些血红蛋白病（即镰状细胞病（SCD））和b-地中海贫血的根本原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.037284},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.039591},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.0244},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.097483},{"month":5,"riseRate":0.571429,"avgChangeRate":0.150972},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.098131},{"month":7,"riseRate":0.428571,"avgChangeRate":0.053699},{"month":8,"riseRate":0.5,"avgChangeRate":0.364873},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.086979},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.097741},{"month":11,"riseRate":0.857143,"avgChangeRate":0.257598},{"month":12,"riseRate":1,"avgChangeRate":0.187927}],"exchange":"NASDAQ","name":"Fulcrum Therapeutics","nameEN":"Fulcrum Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fulcrum Therapeutics(FULC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fulcrum Therapeutics(FULC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fulcrum Therapeutics,FULC,Fulcrum Therapeutics股票,Fulcrum Therapeutics股票老虎,Fulcrum Therapeutics股票老虎国际,Fulcrum Therapeutics行情,Fulcrum Therapeutics股票行情,Fulcrum Therapeutics股价,Fulcrum Therapeutics股市,Fulcrum Therapeutics股票价格,Fulcrum Therapeutics股票交易,Fulcrum Therapeutics股票购买,Fulcrum Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fulcrum Therapeutics(FULC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fulcrum Therapeutics(FULC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}